Generics

First Opinion By Peter Kolchinsky

It’s time to bring generic drug manufacturing back to the U.S.

Pharmalot By Ed Silverman

Johnson & Johnson is fined $30 million for thwarting generics in France

Politics By Nicholas Florko

Supreme Court deals a series of blows to generic drug companies

First Opinion By Dana P. Goldman and Tomas J. Philipson

Biosimilars competition helps patients more than generic competition

Pharmalot By Ed Silverman

Dozens of generic makers and pharmacies won’t face lawsuits over Zantac and cancer risks

Pharmalot By Ed Silverman

Washington may become the second state to distribute its own generic drugs

Pharmalot By Ed Silverman

To the delight of generic drug makers, federal appeals court tosses controversial ‘skinny labeling’ decision

Pharmalot By Ed Silverman

U.S. drug prices were more than double those in dozens of countries in 2018